SmartinBio has raised $149K in funding from 한림제약.
The biotechnology company is developing first-in-class drugs for chemoresistant cancer and retinopathy by targeting the mitochondrial chaperone TRAP1. Founded in 2019 as a spin-off from UNIST research, SmartinBio is working on mitochondria-targeted therapies for intractable diseases, with a pipeline of proprietary TRAP1 inhibitors and a novel mitochondrial drug delivery platform.










